Work

Epinephrine nasal spray for anaphylaxis: a preferred needle-free self-treatment

Year: 2025

Type: article

Abstract: Anaphylaxis is a rapid-onset, potentially fatal allergic reaction that requires immediate epinephrine administration. Traditional intramuscular auto-injectors can be hindered by needle phobia, incorrect use, limited availability, and injection-related injuries. Neffy, the first FDA-approved intranasal epinephrine spray, provides a needle-free, rapid, and user-friendly alternative. Its nasal formulation allows swift absorption, producing pharmacodynamic effects within one minute, comparable to conventional auto-injectors. By eliminating needles, Neffy reduces the risk of lacerations, ischemic complications, and accidental injuries, while enhancing adherence among patients or caregivers hesitant to use injections. Early data indicate effective management of anaphylaxis with this device, though further studies in broader populations are warranted. Adoption of nasal epinephrine may improve timely treatment, increase accessibility, and offer a safer, patient-centered approach to emergency allergic reactions.

Source: Annals of Medicine and Surgery

DOI: 10.1097/ms9.0000000000004653

Authors: Ahmar Jan Qureshi, Kinza Raza, Hibba Iftikhar, Raghabendra Kumar Mahato

Institutions: CMH Multan Institute of Medical Sciences, People's University of Medical and Health Sciences for Women, Gandaki Medical College

Language: English

Topic: Food Allergy and Anaphylaxis Research

Subfield: Immunology and Allergy

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850